Stockreport

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates

Neurogene Inc.  (NGNE) 
PDF 100% of participants enrolled in Embolden™ registrational trial and 50% of participants dosed; on track to complete dosing in second quarter of 2026NGN-401 has been gene [Read more]